Patents Assigned to Yungjin Pharmaceutical Co., Ltd.
-
Patent number: 10328110Abstract: The present invention relates to a composition for promoting osteoblast or cartilage cell differentiation. More particularly, the present invention relates to a composition, which includes stauntonia hexaphylla leaf extract that may be safely used without toxicity and side effects by using a natural ingredient, for promoting bone (tissue) formation to be used for suppressing and treating bone and cartilage tissue damage. A pharmaceutical composition including the stauntonia hexaphylla leaf extract according to the present invention as an active ingredient may be used as a medicine for periodontitis or osteoporosis to treat or prevent periodontitis or osteoporosis.Type: GrantFiled: April 29, 2014Date of Patent: June 25, 2019Assignees: JEONNAM BIOINDUSTRY FOUNDATION, YUNGJIN PHARMACEUTICAL CO., LTD.Inventors: Chul Yung Choi, Sang O Pan, Hee Jin Seol, Gyu Ok Lee, Wook Jin Jang, Hee Sook Kim, Jae Yong Kim, HuWon Kang, Dong Wook Lee, Sun Oh Kim, Jae Gap Kim, JoonYung Park
-
Patent number: 10172816Abstract: A composition comprising a purified extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic response through various in vivo tests as well as in vitro test. Therefore, it can be used as the therapeutics or functional health food for treating and preventing chronic obstructive pulmonary disease (COPD).Type: GrantFiled: December 19, 2016Date of Patent: January 8, 2019Assignees: YUNGJIN PHARMACEUTICAL CO., LTD, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Yongnam Lee, Ji-seok Yoo, Dae-hee Shin, Byung-hwan Ryoo, Kyung Seop Ahn, Sei Ryang Oh, Hyeong Kyu Lee, In Sik Shin, Doo Young Kim, Ok-Kyoung Kwon, Hyuk Hwan Song, Seung Hyung Kim, SuUi Lee
-
Patent number: 10046019Abstract: The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of Pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.Type: GrantFiled: September 11, 2016Date of Patent: August 14, 2018Assignees: YUNGJIN PHARMACEUTICAL CO., LTD, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Yongnam Lee, Ji-seok Yoo, Dae-hee Shin, Byung-hwan Ryoo, Sei-ryang Oh, Kyung-seop Ahn, Hyeongkyu Lee, Ok-kyoung Kwon, Doo-young Kim, Jung-hee Kim, Hyuk-hwan Song
-
Patent number: 9999646Abstract: The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of Pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.Type: GrantFiled: September 11, 2016Date of Patent: June 19, 2018Assignees: YUNGJIN PHARMACEUTICAL CO., LTD, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Yongnam Lee, Ji-seok Yoo, Dae-hee Shin, Byung-hwan Ryoo, Sei-ryang Oh, Kyung-seop Ahn, Hyeongkyu Lee, Ok-kyoung Kwon, Doo-young Kim, Jung-hee Kim, Hyuk-hwan Song
-
Patent number: 9675658Abstract: The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of Pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.Type: GrantFiled: September 11, 2016Date of Patent: June 13, 2017Assignees: YUNGJIN PHARMACEUTICAL CO., LTD, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Yongnam Lee, Ji-seok Yoo, Dae-hee Shin, Byung-hwan Ryoo, Sei-ryang Oh, Kyung-seop Ahn, Hyeongkyu Lee, Ok-kyoung Kwon, Doo-young Kim, Jung-hee Kim, Hyuk-hwan Song
-
Patent number: 9655871Abstract: A composition comprising a purified extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic response through various in vivo tests as well as in vitro test. Therefore, it can be used as the therapeutics or functional health food for treating and preventing chronic obstructive pulmonary disease (COPD).Type: GrantFiled: April 9, 2014Date of Patent: May 23, 2017Assignees: YUNGJIN PHARMACEUTICAL CO., LTD., KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Yongnam Lee, Ji-seok Yoo, Dae-hee Shin, Byung-hwan Ryoo, Kyung Seop Ahn, Sei Ryang Oh, Hyeong Kyu Lee, In Sik Shin, Doo Young Kim, Ok-Kyoung Kwon, Hyuk Hwan Song, Seung Hyung Kim, SuUi Lee
-
Patent number: 9592263Abstract: A method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of Pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.Type: GrantFiled: December 23, 2013Date of Patent: March 14, 2017Assignees: YUNGJIN PHARMACEUTICAL CO., LTD., KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Yongnam Lee, Ji-seok Yoo, Dae-hee Shin, Byung-hwan Ryoo, Sei-ryang Oh, Kyung-seop Ahn, Hyeongkyu Lee, Ok-kyoung Kwon, Doo-young Kim, Jung-hee Kim, Hyuk-hwan Song
-
Publication number: 20160113979Abstract: The present invention relates to a composition for promoting osteoblast or cartilage cell differentiation. More particularly, the present invention relates to a composition, which includes stauntonia hexaphylla leaf extract that may be safely used without toxicity and side effects by using a natural ingredient, for promoting bone (tissue) formation to be used for suppressing and treating bone and cartilage tissue damage. A pharmaceutical composition including the stauntonia hexaphylla leaf extract according to the present invention as an active ingredient may be used as a medicine for periodontitis or osteoporosis to treat or prevent periodontitis or osteoporosis.Type: ApplicationFiled: April 29, 2014Publication date: April 28, 2016Applicants: YUNGJIN PHARMACEUTICAL CO., LTD., Jeonnam Bioindustry FoundationInventors: Chul Yung CHOI, Sang O PAN, Hee Jin SEOL, Gyu Ok LEE, Wook Jin JANG, Hee Sook KIM, Jae Yong KIM, HuWon KANG, Dong Wook LEE, Sun Oh KIM, Jae Gap KIM, JoonYung PARK
-
Patent number: 7009053Abstract: The present invention relates to new quinoline derivatives of formula (1) or their pharmaceutically acceptable salts with caspase-3 inhibitory activity and their preparation methods, wherein R2 is H; halogen; C1-6alkyl; C1-6 alkoxy; C1-6 alkoxyalkyl; or C3-6cycloalkyl; R1 is formula (a); —CN; or formula (b); R is H; C6-14aryl unsubstituted or substituted by halogen, C1-6 alkyl, C1-6 alkoxy or amino; 5–15 membered heterocyclic group unsubstituted or substituted by halogen, C1-6 alkyl, C1-6 alkoxy or amino; or —(CH2)n—CHR4R5. The present invention relates to a pharmaceutical composition for treating caspase-associated diseases by inhibiting the activity of caspase-3 which comprises the compound of formula (1) or its pharmaceutically acceptable salt.Type: GrantFiled: April 30, 2003Date of Patent: March 7, 2006Assignees: Yungjin Pharmaceuticals Co., Ltd., Korea Research Institute of Chemical TechnologyInventors: Sung-Gyu Kim, Yoon Sung Jung, Jae Yang Kong, Woo Kyu Park
-
Patent number: 6043373Abstract: A thiazole compound represented by general formula (I), wherein R is hydrogen atom, a hydroxy group, a straight or branched C.sub.1 -C.sub.6 lower alkyl group, a C.sub.1 -C.sub.4 lower alkoxy group, phenyl group, a phenyl group having one to three substituents selected from a group consisting of a C.sub.1 -C.sub.4 lower alkyl group, a C.sub.1 -C.sub.4 lower alkoxy group, fluorine, chlorine, bromine and an amino group, a C.sub.1 -C.sub.5 alkylphenyl group, a phenyl group having one to three substituents selected from a group consisting of a C.sub.1 -C.sub.4 lower alkyl group, a C.sub.1 -C.sub.4 lower alkoxy group, fluorine, chlorine, bromine and an amino group, a substituted or unsubstituted guanidino group, or an amino group having a general formula: NR.sub.3 R.sub.4 in which R.sub.3 and R.sub.4, identical to or different from each other, represent independently a hydrogen atom, a C.sub.1 -C.sub.6 lower alkyl group, a C.sub.3 -C.sub.Type: GrantFiled: July 3, 1997Date of Patent: March 28, 2000Assignee: Yungjin Pharmaceutical Co., Ltd.Inventors: Han Yong Yoo, Kae Jong Chung, Jun Pyo Chai, Man Sik Chang, Sung Gyu Kim, Wahn Soo Choi, Young Hun Kim, Jae Kwang Chun, Young Kuk Chung, Young Heui Kim, Jang Hoon Paek, Kwi Hyon Seo, Dae Pil Kang
-
Patent number: 5731007Abstract: The present invention relates to novel pharmaceutical composition for skin diseases, in particular to novel pharmaceutical composition useful for treatment of skin diseases; e.g. burns, wounds, general operative wounds, pernio, decubitus, folliculitis, impetigo, intertrigo, radiation ulcer, acne vulgaris or infectious eczematous dermatitis comprising deproteinized dialysate of calf's blood with tissue regenerative activity and aminoglycoside antibiotic with bacterial infection inhibitory activity as active ingredients.Type: GrantFiled: July 25, 1996Date of Patent: March 24, 1998Assignee: Yungjin Pharmaceutical Co., Ltd.Inventors: Kae Jong Chung, Man Sik Chang, Jong Ok Chun, Jae Kwang Chun, Wahn Soo Choi, Sung Chul Kim